Table 1

Assessment protocol in the LABSP

	Time points
Measure	T₀ (enrolment)	T₁(6 months)	T₂ (12 months)	T₃ (18 months)	T₄ (24 months)
BDNF serum levels	✓	✓	✓	✓	✓
Descriptive variables
Demographic data	✓
Socioeconomic data	✓
Clinical history	✓
Family history	✓
Psychopathology
SCID-I/P	✓
SCID-II	✓
PANSS	✓	✓	✓	✓	✓
CGI-SCH	✓	✓	✓	✓	✓
POLTQ	✓
PAS	✓	✓	✓	✓	✓
Social functioning and quality of life
PSP	✓	✓	✓	✓	✓
SWN-S	✓	✓	✓	✓	✓
WHOQOL-Bref	✓	✓	✓	✓	✓
Cognition
BACS	✓	✓	✓	✓	✓
Assessment of side effects
DOTES	✓	✓	✓	✓	✓
ESRS	✓	✓	✓	✓	✓
Biometric, metabolic and cardiovascular measures
Lipid profile	✓				✓
Kidney panel	✓				✓
Liver panel	✓				✓
Electrolytes	✓				✓
Weight, height, waist circumference, BMI	✓	✓	✓	✓	✓
Glucose	✓				✓
Glycosylated haemoglobin	✓				✓
PRL	✓				✓
CPK	✓				✓
ECG	✓				✓

BACS, Brief Assessment of Cognition in Schizophrenia; BDNF, brain-derived neurotrophic factor; BMI, body mass index; CGI-SCH, Clinical Global Impression Scale for Schizophrenia; CPK, creatine phosphokinase; DOTES, Dosage Record Treatment Emergent Symptom Scale; ESRS, Extrapyramidal Symptom Rating Scale; LABSP, Longitudinal assessment of BDNF in Sardinian psychotic patients; PANSS, Positive and Negative Syndrome Scale; PAS, Premorbid Adjustment Scale; POLTQ, Psychopathological Onset Latency and Treatment Questionnaire; PRL, prolactin; PSP, Personal and Social Performance Scale; SCID-II, Structured Clinical Interview for DSM IV Axis II Disorders; SCID-I/P, Structured Clinical Interview for DSM IV Axis I Disorders; SWN-S, Subjective Well-Being under Neuroleptics-Short Version; WHOQOL-Bref, WHO Quality of Life—Bref.